Low-cost treatment for multiple sclerosis shown to be as effective as standard therapy

A Norwegian-Swedish objective proceedings published successful the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is arsenic effectual arsenic ocrelizumab successful recently diagnosed relapsing aggregate sclerosis (MS). The study, known arsenic OVERLORD-MS, is the archetypal randomized, double-blind, head-to-head proceedings comparing the 2 therapies successful aboriginal MS. Patients from crossed Norway and Sweden were followed for 30 months with MRI and objective assessments.